Translational aspect in peptide drug discovery and development: An emerging therapeutic candidate

Abstract

In the last two decades, protein-protein interactions (PPIs) have been used as the main target for drug development. However, with larger or superficial binding sites, it has been extremely difficult to disrupt PPIs with small molecules. On the other hand, intracellular PPIs cannot be targeted by antibodies that cannot penetrate the cell membrane. Peptides that have a combination of conformational rigidity and flexibility can be used to target difficult binding interfaces with appropriate binding affinity and specificity. Since the introduction of insulin nearly a century ago, more than 80 peptide drugs have been approved to treat a variety of diseases. These include deadly diseases such as cancer and human immunodeficiency virus infection. It is also useful against diabetes, chronic pain, and osteoporosis. Today, more research is being done on these drugs as lessons learned from earlier approaches, which are still valid today, complement newer approaches such as peptide display libraries. At the same time, integrated genomics and peptide display libraries are new strategies that open new avenues for peptide drug discovery. The purpose of this review is to examine the problems in elucidating the peptide-protein recognition mechanism. This is important to develop peptide-based interventions that interfere with endogenous protein interactions. New approaches are being

Nano‐biotechnology in tumour and cancerous disease: A perspective review

“…Second, the surface of the material can be modified to improve its biological targeting properties by adding chemicals that interact with tumour cells. Finally, the biodegradability of nanomaterials used in biomimetic fabrication and modification of nanomaterials for controlled cancer detection and therapy can be improved by using biomolecules such as proteins, DNA and peptides [204][205][206]. In recent years, there has been a lot of buzz about a new type of cancer treatment called gas therapy (GT).…”

Dock-able linear and homodetic di, tri, tetra and pentapeptide library from canonical amino acids: SARS-CoV-2 Mpro as a case study

“…[ 1 ]. As of this writing, over 80 unique peptide drugs have been approved worldwide, while over 150 are in development [ 2 , 3 ].…”

Dock-able linear and homodetic di, tri, tetra and pentapeptide library from canonical amino acids: SARS-CoV-2 Mpro as a case study

“…[1]. As of this writing, more than 80 unique peptide drugs have been approved worldwide, while over 150 are in development [2,3].…”